The Patent Cliff Is Why AbbVie Is Moving Higher

AbbVie NYSE: ABBV shares have been under pressure for the last 2 years as fears of the patent cliff gripped the market. The fear of rapidly declining Humira sales was not offset by hope driven by new products such as Skyrizi and Rinvoq. The takeaway for today is that Humira sales may already be…#humira #rinvoq #skrizi #abbvie #yoy #skyriziandrinvoq #hematologyoncology #botox #eps #marketbeatcom

Source: Reuters: Health - July 28, 2023 Category: Consumer Health News Source Type: news